Despite the advent of new therapeutic strategies and technologies to improve type 1 diabetes mellitus (T1DM) management, target glycemic control is not systematically achieved and further optimization of therapy is hindered by hypoglycemia and weight gain.[1–5] Akin to studies in type 2 diabetes,[6–8] sodium glucose cotransporter-2 (SGLT2) inhibitors may be effective as adjunctive-to-insulin therapy in T1DM to favourably improve glycemic control, hypoglycemia risk, and the weight gain associated with over-insulinization.[9–15]. Here, SLC5A2 is linked to type 1 diabetes mellitus.